/

Sociétés

Ce

Non vérifié

Cellares

Ce que nous écrivons

BiotechnologieIndustrieIndustrie pharmaceutiqueMarché du travailSanté

30 communiqués de presse

Voir tous les communiqués de presse

21/07/2026

Cellares and Papillon Therapeutics Partner to Automate Manufacturing of PPL-001 for Patients With Friedreich’s Ataxia

Source

Émetteur

1.00

0

13/07/2026

Cellares and Sonoma Biotherapeutics Collaborate to Automate Manufacturing of SBT-77-7101 Engineered Treg Cell Therapy on the Cell Shuttle® Platform

Source

Émetteur

1.00

0

30/06/2026

Cellares Accepted to FDA's Inaugural Manufacturing PreCheck Cohort, the Only Cell Therapy Platform Among Seven Companies Nationwide

Source

Émetteur

1.00

0

15/06/2026

Cellares Grows Series D to $327 Million with $50 Million Prime Radiant Partners Investment

Source

Émetteur

1.00

0

10/06/2026

Cellares Joins New American Industrial Alliance, Advancing U.S. Biopharmaceutical Manufacturing Independence

Source

Émetteur

1.00

0

09/06/2026

Cathie Wood's ARK Invest Joins Cellares' $277 Million Series D

Source

Émetteur

1.00

0

03/06/2026

Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies

Source

Émetteur

1.00

0

11/05/2026

Cellares and ProTgen Partner to Automate Manufacturing for ProT-096, a Novel Progenitor T Cell Therapy Designed to Restore Immune Competence

Source

Émetteur

1.00

0

28/04/2026

Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel

Source

Émetteur

1.00

0

14/04/2026

First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform

Source

Émetteur

1.00

0

Followers

0

Compatibilité

0